BTIG Research Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a research report issued on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 142.72% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Wednesday, July 1st. Weiss Ratings cut shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Finally, Roth Capital restated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Gain Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $2.06 on Tuesday. Gain Therapeutics has a twelve month low of $1.46 and a twelve month high of $4.34. The company has a market cap of $87.86 million, a PE ratio of -3.55 and a beta of 0.19. The business’s 50 day moving average price is $1.79 and its two-hundred day moving average price is $1.93. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. On average, analysts predict that Gain Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GANX. BlackRock Inc. bought a new stake in shares of Gain Therapeutics in the second quarter worth $558,000. GSA Capital Partners LLP bought a new position in Gain Therapeutics during the 2nd quarter worth $1,283,000. Apollon Wealth Management LLC lifted its holdings in Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after buying an additional 6,675 shares during the period. Millennium Management LLC acquired a new position in Gain Therapeutics during the 4th quarter worth about $45,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $47,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.